Difference between revisions of "ALK translocation renal cell carcinoma"

From Libre Pathology
Jump to navigation Jump to search
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{ Infobox diagnosis
| Name      = {{PAGENAME}}
| Image      =
| Width      =
| Caption    =
| Synonyms  =
| Micro      = mixed morphology, +/-papillae, +/-myxoid change
| Subtypes  =
| LMDDx      = [[papillary renal cell carcinoma]], [[unclassified renal cell carcinoma]], [[clear cell renal cell carcinoma]], [[SMARCB1-deficient renal medullary carcinoma]]
| Stains    =
| IHC        = ALK +ve
| EM        =
| Molecular  = ALK rearranagement
| IF        =
| Gross      =
| Grossing  = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]]
| Staging    = [[kidney cancer staging]]
| Site      = [[kidney]] - see ''[[kidney tumours]]''
| Assdx      =
| Syndromes  =
| Clinicalhx =
| Signs      =
| Symptoms  =
| Prevalence = very rare
| Bloodwork  =
| Rads      =
| Endoscopy  =
| Prognosis  =
| Other      =
| ClinDDx    =
| Tx        = may respond to ALK inhibitors
}}
'''ALK translocation renal cell carcinoma''', also '''ALK-rearranged renal cell carcinoma''' and '''ALK-positive renal cell carcinoma''', is a type of [[renal cell carcinoma]] recognized by the WHO.
'''ALK translocation renal cell carcinoma''', also '''ALK-rearranged renal cell carcinoma''' and '''ALK-positive renal cell carcinoma''', is a type of [[renal cell carcinoma]] recognized by the WHO.


==General==
==General==
*Extremely rare.
*Extremely rare.
**1 in 829 consecutively screened patients.<ref name=pmid24255633>{{Cite journal  | last1 = Lee | first1 = C. | last2 = Park | first2 = JW. | last3 = Suh | first3 = JH. | last4 = Nam | first4 = KH. | last5 = Moon | first5 = KC. | title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. | journal = Korean J Pathol | volume = 47 | issue = 5 | pages = 452-7 | month = Oct | year = 2013 | doi = 10.4132/KoreanJPathol.2013.47.5.452 | PMID = 24255633 }}</ref>
**One case was identified in 829 consecutively screened Korean patients.<ref name=pmid24255633>{{Cite journal  | last1 = Lee | first1 = C. | last2 = Park | first2 = JW. | last3 = Suh | first3 = JH. | last4 = Nam | first4 = KH. | last5 = Moon | first5 = KC. | title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. | journal = Korean J Pathol | volume = 47 | issue = 5 | pages = 452-7 | month = Oct | year = 2013 | doi = 10.4132/KoreanJPathol.2013.47.5.452 | PMID = 24255633 }}</ref>
**A second series described 8 in 276 cases on a microarray.<ref name=pmid38039739>{{cite journal |authors=Doğan K, Onder E |title=ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey |journal=Pathol Res Pract |volume=253 |issue= |pages=154951 |date=January 2024 |pmid=38039739 |doi=10.1016/j.prp.2023.154951 |url=}}</ref>
**A second series described 8 in 276 cases on a microarray.<ref name=pmid38039739>{{cite journal |authors=Doğan K, Onder E |title=ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey |journal=Pathol Res Pract |volume=253 |issue= |pages=154951 |date=January 2024 |pmid=38039739 |doi=10.1016/j.prp.2023.154951 |url=}}</ref>
**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>
**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>
Line 29: Line 61:
*CK7 +ve (focal).
*CK7 +ve (focal).
*[[SMARCB1]] normal nuclear staining.{{fact}}
*[[SMARCB1]] normal nuclear staining.{{fact}}
==Molecular==
*ALK rearrangement.


==See also==
==See also==

Latest revision as of 14:39, 16 December 2024

ALK translocation renal cell carcinoma
Diagnosis in short
LM mixed morphology, +/-papillae, +/-myxoid change
LM DDx papillary renal cell carcinoma, unclassified renal cell carcinoma, clear cell renal cell carcinoma, SMARCB1-deficient renal medullary carcinoma
IHC ALK +ve
Molecular ALK rearranagement
Grossing notes total nephrectomy for tumour grossing, partial nephrectomy grossing
Staging kidney cancer staging
Site kidney - see kidney tumours
Prevalence very rare
Treatment may respond to ALK inhibitors

ALK translocation renal cell carcinoma, also ALK-rearranged renal cell carcinoma and ALK-positive renal cell carcinoma, is a type of renal cell carcinoma recognized by the WHO.

General

  • Extremely rare.
    • One case was identified in 829 consecutively screened Korean patients.[1]
    • A second series described 8 in 276 cases on a microarray.[2]
    • In 2016, less than 17 cases reported.[3]
  • May respond to ALK inhibitors such as alectinib[4] or crizotinib.[3]

Microscopic

Features:

DDx:

IHC

Features:[6]

Molecular

  • ALK rearrangement.

See also

References

  1. ↑ 1.0 1.1 1.2 Lee, C.; Park, JW.; Suh, JH.; Nam, KH.; Moon, KC. (Oct 2013). "ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients.". Korean J Pathol 47 (5): 452-7. doi:10.4132/KoreanJPathol.2013.47.5.452. PMID 24255633.
  2. ↑ 2.0 2.1 Doğan K, Onder E (January 2024). "ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey". Pathol Res Pract 253: 154951. doi:10.1016/j.prp.2023.154951. PMID 38039739.
  3. ↑ 3.0 3.1 Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.
  4. ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.
  5. ↑ Kuroda, N.; Karashima, T.; Inoue, K.; Kasajima, A.; Ohe, C.; Kawakami, F.; Mikami, S.; Matsuura, K. et al. (Mar 2015). "Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects.". Pol J Pathol 66 (1): 3-8. PMID 26017874.
  6. ↑ Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.
Retrieved from "https://librepathology.org/w/index.php?title=ALK_translocation_renal_cell_carcinoma&oldid=53361"